down arrow

Neurogene, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US64135M1053
USD
20.55
1.27 (6.59%)

Dec 19

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

19.4820.77

52 Week

6.8837.20
Valuation
Technical
Day's Volume

CASH

168.7 k

Shareholding (Mar 2025)

FII

4.90%

Held by 37 FIIs

DII

67.9%

Held by 18 DIIs

Promoter

11.15%

What does Neurogene, Inc. do?

22-Jun-2025

Neurogene, Inc. is a Micro Cap company in the Pharmaceuticals & Biotechnology industry. It currently has no available net sales or profit, a 0.00% dividend yield, and significant negative debt equity and return on equity metrics.

Overview:<BR>Neurogene, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: Not available<BR>Most recent Net Profit: Not available<BR>Market-cap: Micro Cap<BR><BR>Key Metrics:<BR>Industry: Pharmaceuticals & Biotechnology<BR>Market cap: Micro Cap<BR>Dividend Yield: 0.00%<BR>Debt Equity: -999,999.00<BR>Return on Equity: -999,999.00%<BR>Price to Book: 0.00<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Read More

Is Neurogene, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Neurogene, Inc. shows a mildly bullish trend change, but mixed technical indicators and significant underperformance compared to the S&P 500 suggest a cautiously optimistic outlook with potential risks.

As of 11 September 2025, the technical trend for Neurogene, Inc. has changed from sideways to mildly bullish. However, the overall technical stance remains mixed. The weekly MACD is bearish while the monthly MACD is mildly bullish. Moving averages indicate a mildly bullish trend on the daily timeframe. The Bollinger Bands and KST show bearish signals on the weekly, with the KST also bearish on the monthly. Dow Theory presents a mildly bearish stance on the weekly but is mildly bullish on the monthly.<BR><BR>Despite the mildly bullish trend change, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -18.29% versus the S&P 500's 12.22%, and a one-year return of -54.77% compared to 17.14% for the index. Overall, the indicators suggest a cautiously optimistic outlook, but the bearish signals in the weekly timeframe indicate potential risks.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 278 Million ()

stock-summary
P/E

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.99

stock-summary
Return on Equity

-999,999.00%

stock-summary
Price to Book

1.02

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-22 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
19.48%
0%
19.48%
6 Months
12.3%
0%
12.3%
1 Year
-6.91%
0%
-6.91%
2 Years
36.09%
0%
36.09%
3 Years
131.94%
0%
131.94%
4 Years
-79.77%
0%
-79.77%
5 Years
-91.05%
0%
-91.05%

Neurogene, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-186.08%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
92.47%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
EV to EBIT
EV to EBITDA
EV to Capital Employed
EV to Sales
PEG Ratio
NA
Dividend Yield
ROCE (Latest)
ROE (Latest)
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 24 Schemes (16.04%)

Foreign Institutions

Held by 37 Foreign Institutions (4.9%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -100.00% vs 0.00% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -18.92% vs -780.95% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.90",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-25.30",
          "val2": "-19.30",
          "chgp": "-31.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-22.00",
          "val2": "-18.50",
          "chgp": "-18.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-21,766.50%",
          "chgp": "2,176.65%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -106.89% vs 34.24% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-79.40",
          "val2": "-52.30",
          "chgp": "-51.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-75.10",
          "val2": "-36.30",
          "chgp": "-106.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-89,302.70%",
          "val2": "0.00%",
          "chgp": "-8,930.27%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.90
-100.00%
Operating Profit (PBDIT) excl Other Income
-25.30
-19.30
-31.09%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-22.00
-18.50
-18.92%
Operating Profit Margin (Excl OI)
0.00%
-21,766.50%
2,176.65%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is -100.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -18.92% vs -780.95% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.90
0.00
Operating Profit (PBDIT) excl Other Income
-79.40
-52.30
-51.82%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-75.10
-36.30
-106.89%
Operating Profit Margin (Excl OI)
-89,302.70%
0.00%
-8,930.27%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -106.89% vs 34.24% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Neurogene, Inc. stock-summary
stock-summary
Neurogene, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."